我要投票 易乎生物在化学药物行业中的票数:408
· 外 推 电 报 ·
2025-08-25 00:15:29 星期一

【易乎生物是哪个国家的品牌?】

易乎生物是什么牌子?「易乎生物」是 上海易乎生物科技有限公司 旗下著名品牌。该品牌发源于上海,由创始人许向军在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力易乎生物品牌出海!将品牌入驻外推网,定制易乎生物品牌推广信息,可以显著提高易乎生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

随着经济的高速发展,人类社会对资源的需求越来越大,资源的严重匮乏已经是制约经济发展的重要因素之一。能否节约能源已经是衡量一个企业能否持续发展的关键因素。高效地利用能源是易乎创办的基本理念。

易乎是有位于美国新泽西州的易乎营养与健康有限责任公司和位于上海浦东张江高科技园区的上海易乎生物科技有限公司组成。在新泽西及奉贤开发区有研发和生产基地。公司是有有多年从事营养与健康研究,生物制品及药物研究的科研人员创办的集研发、生产与销售一体的高科技公司。我们与美国罗格斯大学和上海药物研究所有广泛的合作关系。公司主要从事营养与健康制品,生物制品,抗菌产品,药品原料,纳米中成药材等的开发与生产。目前,氧化硅磁珠,阻燃剂,纳米姜黄素、复合纳米二氧化钛,各种功能性食品、药品、健康制品添加剂,高效纳米银抗菌粉等一系列产品已经取得了广泛地认可。我们在两地都有相关业务的进出口权。同时,我们还会根据客户的需要研发相关的产品。

经过十几年的发展,我们的产品已经成功销往北美、欧洲、南亚等国家和地区, 国内已有多家跨国公司使用。质量第一、客户为上,基于双赢的经营理念,我们竭诚为广大客户服务。

公司主要从事营养与健康制品,生物制品,抗菌产品,药品原料,纳米中成药材等的开发与生产。目前,氧化硅磁珠,阻燃剂,纳米姜黄素、复合纳米二氧化钛,各种功能性食品、药品、健康制品添加剂,高效纳米银抗菌粉等一系列产品已经取得了广泛地认可。我们在两地都有相关业务的进出口权。

英文翻译:With the rapid development of economy, the demand of human society for resources is increasing. The serious shortage of resources has been one of the important factors restricting economic development. Energy saving is the key factor to measure the sustainable development of an enterprise. Efficient use of energy is the basic idea of Yihu. Yihu is composed of Yihu nutrition and health Co., Ltd. located in New Jersey, USA and Shanghai Yihu Biotechnology Co., Ltd. located in Zhangjiang High Tech Park, Pudong, Shanghai. There are R & D and production bases in New Jersey and Fengxian development zone. The company is a high-tech company founded by researchers who have been engaged in nutrition and health research, biological products and drug research for many years. We have extensive partnerships with Rutgers University and Shanghai pharmaceutical research. The company is mainly engaged in the development and production of nutrition and health products, biological products, antibacterial products, pharmaceutical raw materials, nano Chinese medicine, etc. At present, a series of products, such as silicon oxide beads, flame retardants, curcumin nanoparticles, composite nano titanium dioxide, various functional food, medicine, health product additives, and highly effective nano silver antibacterial powder, have been widely recognized. We have the right to import and export related business in both places. At the same time, we will develop relevant products according to the needs of customers. After more than ten years of development, our products have been successfully sold to North America, Europe, South Asia and other countries and regions. Quality first, customer-oriented, based on the win-win business philosophy, we are dedicated to serving our customers. The company is mainly engaged in the development and production of nutrition and health products, biological products, antibacterial products, pharmaceutical raw materials, nano Chinese medicine, etc. At present, a series of products, such as silicon oxide beads, flame retardants, curcumin nanoparticles, composite nano titanium dioxide, various functional food, medicine, health product additives, and highly effective nano silver antibacterial powder, have been widely recognized. We have the right to import and export related business in both places.

本文链接: https://www.waitui.com/brand/56179780f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格林美:筹划发行H股股票并在香港联交所上市

36氪获悉,格林美发布公告,经充分研究论证,董事会同意公司发行H股股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况,在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行上市。截至目前,公司正积极与相关中介机构就本次发行上市的相关工作进行商讨,除本次董事会、监事会审议通过的相关议案外,其他关于本次发行上市的具体细节尚未最终确定。

16分钟前

中信证券:预计未来中国前列腺癌RDC诊疗市场将超100亿元

36氪获悉,中信证券研报表示,创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求,改变前列腺癌诊疗范式,实现诊疗一体化,提高患者依从性和生存期。目前中国尚无任何RDC上市,市场呈现蓝海状态,海外前列腺癌RDC诊疗产品在2021年上市,2024年市场已接近30亿美元,充分验证了其巨大的商业价值。中信证券认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径,预计未来中国前列腺癌RDC诊疗市场将超100亿元,市场呈现高速增长状态。该行业关键点为核素、配体分子形态、生产配送能力,建议关注在上述条件具有优势的公司。

16分钟前

​锡业股份:上半年净利润10.62亿元,同比增长32.76%

36氪获悉,锡业股份披露2025年半年报,上半年实现营业收入210.93亿元,同比增长12.35%;归属于上市公司股东的净利润10.62亿元,同比增长32.76%;基本每股收益0.626元。

16分钟前

亚世光电:上半年净利润538.04万元,同比下降36.21%

36氪获悉,亚世光电披露2025年半年报,上半年实现营业收入4.32亿元,同比增长30.01%;归属于上市公司股东的净利润538.04万元,同比下降36.21%;基本每股收益0.0331元。

16分钟前

金螳螂:上半年净利润3.58亿元,同比增长3.95%

36氪获悉,金螳螂披露2025年半年报,上半年实现营业收入95.28亿元,同比增长2.49%;归属于上市公司股东的净利润3.58亿元,同比增长3.95%;基本每股收益0.1348元。

16分钟前

本页详细列出关于易乎生物的品牌信息,含品牌所属公司介绍,易乎生物所处行业的品牌地位及优势。
咨询